Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Better Therapeutics Inc
(NQ:
BTTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Better Therapeutics Inc
< Previous
1
2
3
Next >
Better Therapeutics to Participate in BTIG Digital Health Forum
November 15, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 14, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 14, 2022
November 07, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer
October 27, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Positive Results from Pivotal Trial of Better Therapeutics’ Investigational BT-001 Prescription Digital Therapy for Type 2 Diabetes Published in Diabetes Care
October 04, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes
September 22, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Participate in Three Upcoming Investor Conferences
September 07, 2022
From
Better Therapeutics
Via
Business Wire
Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
August 04, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results
July 28, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes
July 26, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001, a Novel Prescription Digital Therapy, in Clinical Cardiology
July 11, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference
June 16, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Participate in Cowen’s Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022
June 09, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics Platform
June 08, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Appoints Frank Karbe as Chief Executive Officer
June 07, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Host Virtual Educational Webinar Symposium on New American Diabetes Association Guidelines Recommending Digital Tools in Diabetes Care
May 19, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate Milestones
May 13, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 13, 2022
May 05, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Announces Key Milestones and Updates for Ongoing Studies of its Digital Therapeutics Approach for Cardiometabolic Diseases
April 06, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Participate in Chardan’s Virtual Prescription Digital Therapeutics Summit
April 04, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Host Call Detailing Promising Results from Pivotal Clinical Trial for Type 2 Diabetes Digital Therapeutics
March 23, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Announces Positive Primary Endpoint Data From Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients With Uncontrolled Type 2 Diabetes
March 15, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research
February 16, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics to Participate in Two Upcoming Investor Events
January 20, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Highlights Recent Progress and Updates Outlook Through Q1 2022
January 06, 2022
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Appoints Deepti Sodhi Jaggi, PharmD, as Chief Strategy Officer
November 30, 2021
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Completes Enrollment of Pivotal Trial for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes
November 18, 2021
From
Better Therapeutics, Inc.
Via
Business Wire
Better Therapeutics Appoints Major General Elder Granger, M.D., U.S. Army (retired) to its Board of Directors
November 11, 2021
From
Better Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.